Salivary hypersecretion and Upper respiratory tract infection

Summary:

Upper respiratory tract infection is found among people with Salivary hypersecretion, especially for people who are male, 20-29 old.

The study analyzes which people have Upper respiratory tract infection with Salivary hypersecretion. It is created by eHealthMe based on reports of 10 people who have Salivary hypersecretion from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 30, 2022

10 people who have Salivary Hypersecretion and Upper Respiratory Tract Infection are studied.


What is Salivary hypersecretion?

Salivary hypersecretion (excess saliva secretion) is found to be associated with 1,997 drugs and 1,193 conditions by eHealthMe.

What is Upper respiratory tract infection?

Upper respiratory tract infection is found to be associated with 2,403 drugs and 1,565 conditions by eHealthMe.

Number of Upper respiratory tract infection in Salivary hypersecretion reports submitted per year:

Would you have Upper respiratory tract infection when you have Salivary hypersecretion?

Gender of people who have Salivary Hypersecretion and experienced Upper Respiratory Tract Infection *:

  • female: 40 %
  • male: 60 %

Age of people who have Salivary Hypersecretion and experienced Upper Respiratory Tract Infection *:

  • 0-1: 0.0 %
  • 2-9: 10 %
  • 10-19: 0.0 %
  • 20-29: 40 %
  • 30-39: 30 %
  • 40-49: 0.0 %
  • 50-59: 20 %
  • 60+: 0.0 %

Common co-existing conditions for these people *:

  1. Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 6 people, 60.00%
  2. Indigestion: 4 people, 40.00%
  3. High Blood Pressure: 4 people, 40.00%
  4. High Blood Cholesterol: 4 people, 40.00%
  5. Psychotic Disorder: 3 people, 30.00%
  6. Stress And Anxiety: 2 people, 20.00%
  7. Seizures (abnormal excessive or synchronous neuronal activity in the brain): 1 person, 10.00%
  8. Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 1 person, 10.00%
  9. Hypersensitivity: 1 person, 10.00%
  10. Gastrointestinal Hypomotility (less activity of the intestinal tract): 1 person, 10.00%

Common drugs taken by these people *:

  1. Clozaril: 7 people, 70.00%
  2. Ramipril: 4 people, 40.00%
  3. Fenofibrate: 4 people, 40.00%
  4. Amisulpride: 4 people, 40.00%
  5. Lansoprazole: 3 people, 30.00%
  6. Senna: 1 person, 10.00%
  7. Miralax: 1 person, 10.00%
  8. Flonase: 1 person, 10.00%
  9. Dysport: 1 person, 10.00%
  10. Cuvposa: 1 person, 10.00%

Common symptoms for these people *:

  1. High Blood Cholesterol: 6 people, 60.00%
  2. Liver Function Test Abnormal: 4 people, 40.00%
  3. Neuroleptic Malignant Syndrome (a life-threatening neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic agents): 4 people, 40.00%
  4. Cough: 4 people, 40.00%
  5. Influenza Like Illness: 4 people, 40.00%
  6. Myositis (inflammation of the muscles): 4 people, 40.00%
  7. Nasopharyngitis (inflammation of the nasopharynx): 4 people, 40.00%
  8. Blood Creatine Phosphokinase Increased: 4 people, 40.00%
  9. Neutrophil Count Increased (excess than normal number of neutrophil a type of blood cell): 4 people, 40.00%
  10. Oropharyngeal Pain: 4 people, 40.00%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Upper respiratory tract infection?

Check whether Upper respiratory tract infection is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Treatments, associated drugs and conditions:

COVID vaccines that are related to Upper respiratory tract infection:

Common drugs associated with Upper respiratory tract infection:

All the drugs that are associated with Upper respiratory tract infection:

Common conditions associated with Upper respiratory tract infection:

All the conditions that are associated with Upper respiratory tract infection:

How the study uses the data?

The study is based on Upper respiratory tract infection and Salivary hypersecretion, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: